Epoetin alpha

ApprovedSmall molecule

UUniversity Medical Center Groningen

Epoetin alpha is one of 133 small molecule programs targeting Ischemia. It is currently in Approved.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

AnemiaActive, not recruiting

Myocardial IschemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

IschemiaPreclinical

Active, not recruiting

AnemiaApproved

Active, not recruiting

Myocardial IschemiaPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Epoetin alpha

UUniversity Medical Center Groningen

Approved

1 2

Aranesp

Amgen

Preclinical

40 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 4

Uloric

Takeda

Preclinical

3 5

Lorelco

Sanofi

Preclinical

1 6

Sovaldi

Gilead

Preclinical

1 7

Glucotrol

Pfizer

Preclinical

1 8

Vemlidy

Gilead

Preclinical

1 9

Activase

Flomax

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

Terminated·AAzidus Brasil·Phase 3·NCT01695759·92 enrolled

Erythropoietin1 trial

Optimized Erythropoietin (EPO) Treatment

Completed·JJohn A Widness·Phase 2·NCT02075970·62 enrolled

Anemia1 trial

Prevalence and Treatment of Anemia in Rehabilitation Patients

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 4·NCT00511901·22 enrolled

Ischemia1 trial

Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model

Unknown status·UUniversity Medical Center Groningen·N/A·NCT00691613·12 enrolled

Myocardial Ischemia1 trial

Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia

Completed·UUniversity Medical Center Groningen·Phase 2·NCT00524901·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Epoetin alpha. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epoetin alpha compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epoetin alpha. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Center Groningen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity Medical Center Groningen

Epoetin alpha

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease1 trial

Erythropoietin1 trial

Anemia1 trial

Ischemia1 trial

Myocardial Ischemia1 trial

References

Drug Info

Quick Facts

Related News